According to a recent report by Bloomberg, Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average rating of “Buy” from seven research firms that are currently covering the company. These research analysts have unanimously given the stock a buy recommendation. Additionally, the average one-year price objective among brokers who have covered the stock in the past year is $17.88.
On Wednesday, Cabaletta Bio’s stock opened at $13.83. The company has a 50-day moving average of $12.95 and a 200-day moving average of $10.94. With a market capitalization of $550.57 million, Cabaletta Bio operates with a price-to-earnings ratio of -7.99 and a beta of 2.55. Its one-year low stands at $0.59, while its one-year high reaches $16.04.
In terms of shareholder activity, several institutional investors and hedge funds have recently made adjustments to their holdings in Cabaletta Bio (NASDAQ:CABA). Ameritas Investment Partners Inc., for example, acquired a new position in the company during Q2 with an estimated value of $27,000. UBS Group AG also obtained a new position in Q3 valued at approximately $33,000.
Barclays PLC increased its stake in shares of Cabaletta Bio by 239.6% during Q4 and now owns 4,146 shares worth $38,000 after acquiring an additional 2,925 shares during that period. Furthermore, Dynamic Technology Lab Private Ltd raised its holdings by 81.6% during Q1 to reach 19,250 shares valued at $39,000 after obtaining an additional 8,648 shares.
Lastly, Freedom Wealth Alliance LLC recently acquired a new stake in Cabaletta Bio during Q4 worth around $41,000.
https://beststocks.com/cabaletta-bio-receives-buy-rating-from-research-an/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.